Receptor News and Research

RSS

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer

Glioblastoma multiforme is among the most lethal of cancers and the most stubborn in the face of treatment. Fewer than 20 percent of patients survive more than two years after diagnosis, according to the Central Brain Tumor Registry of the United States.

29 Apr 2021

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

In a new study currently available on the bioRxiv* preprint server, a group of US-based researchers developed a panel of neutralizing monoclonal antibodies against SARS-CoV-2 that can block viral attachment to cells – and pinpointed a specific one that can potently neutralize all tested variants of concern.

28 Apr 2021

Recovered COVID-19 patients show signs of long-term immunity

A study conducted by researchers in the United States has found that most patients who recovered from coronavirus disease 2019 (COVID-19) showed signs of long-lasting immunity against the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

28 Apr 2021

Topical therapy can help safely reduce side effect of cancer treatment

Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.

28 Apr 2021

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

The findings reveal that although the two-dose vaccine regimen initially induces robust antibody response in all age groups, older male individuals are particularly associated with a gradual decline in vaccine-induced immunity six weeks after the second vaccine dose.

28 Apr 2021

Can control theory explain differences in virulence and transmission of SARS-CoV-2?

A new study discusses variations in viral pathogenicity and in transmission, which are responsible for asymptomatic infection and for superspreading events. The ability to understand this would open the way to understand how this virus behaves the way it does, in terms of its virulence, its spread, and its emergent variants of concern.

28 Apr 2021

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

A new study reports on a set of antibodies from COVID-19 donor serum, which seems to be cross-reactive across multiple Sarbecoviruses, including the very similar SARS-CoV-2, SARS-CoV and Middle East Respiratory Syndrome (MERS)-CoV.

28 Apr 2021

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

A new study describes a synthetic peptide used as a platform to generate protective adaptive cellular immunity to the virus in rhesus macaques, which are the gold standard for preclinical testing in humans.

28 Apr 2021

SARS-CoV-2 recruits heme metabolites in antibody evasion

A research paper recently published in the journal Science Advances by Cherepanov et al. (April 22nd, 2021) demonstrated that the NTD binds to biliverdin, a product of heme catabolism, leading to enhanced antibody escape at physiologically relevant concentrations.

28 Apr 2021

Why do we lose our sense smell/taste with COVID?

The angiotensin-converting enzyme 2 (ACE2) enzyme attached to the membranes of cells is the entry point for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They are abundantly found all over the body and most prominently in the lungs and nose.

28 Apr 2021

Researchers design "nanotraps" to capture and destroy SARS-CoV-2 viruses

Researchers at the Pritzker School of Molecular Engineering at the University of Chicago have designed a completely novel potential treatment for COVID-19: nanoparticles that capture SARS-CoV-2 viruses within the body and then use the body's own immune system to destroy it.

27 Apr 2021

SARS-CoV-2 clade linked to disease severity in the early phase of the pandemic

A new study in the journal JAMA Network reports on the disease severity associated with some clades of the virus, from an analysis of genomes from specimens isolated in the initial phase of the pandemic.

27 Apr 2021

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

An interesting poster, just presented at the annual meeting of the American Society for Pharmacology and Experimental Therapeutics 2021, reports an association between the use of certain heart medications and the risk of COVID-19.

27 Apr 2021

Study identifies mechanism behind SARS-CoV-2 viral protein production

A new study from German researchers examines how SARS viruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hijack cells and reprogram them to enhance viral replication.

27 Apr 2021

What is the role of nanotechnology in the current COVID-19 outbreak?

The nanotechnology-based medicine platforms against COVID-19 bears hope for relief from the pandemic to save lives and mitigate the infection as part of a broader global public health agenda.

27 Apr 2021

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

A team of scientists recently investigated and compared the efficacy of spike-based and nucleocapsid-based COVID-19 vaccines in mice infected with SARS-CoV-2. Their findings reveal that nucleocapsid-based vaccines are effective in preventing SARS-CoV-2 infection in distal organs, such as the brain.

27 Apr 2021

Researchers develop eleven SARS-CoV-2 RBD nanobodies using computational design

To develop therapeutics that block this binding process, a team of researchers recently used an integrated computational approach to design nanobodies (Nbs) against the SARS-CoV-2 RBD, using neutralizing/monoclonal antibodies specific to RBD of the spike protein.

27 Apr 2021

Triple mutation in SARS-CoV-2 seen in second wave of COVID-19 in India

Researchers sequenced the viral genome from samples in the state of Maharashtra and found a unique combination of three mutations that suggest the SARS-CoV-2 virus is continually evolving to evade the human immune response.

27 Apr 2021

Prolactin hormone acts as a major contributor to breast cancer development, studies find

The hormone prolactin has long been understood to play a vital role in breast growth and development and the production of milk during pregnancy.

27 Apr 2021

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

A team of Australian researchers at the Walter and Eliza Hall Institute of Medical Research (WEHI), the Doherty Institute, and the Kirby Institute have identified neutralizing nanobody cocktails that block the SARS-CoV-2 virus from entering cells in pre-clinical models.

27 Apr 2021

Receptor News and Research

Researchers receive $3.75 million to study the impact of fluid flow on CAR-T cell therapy for brain cancer

Potent monoclonal antibody shows promise against emerging SARS-CoV-2 variants of concern

Recovered COVID-19 patients show signs of long-term immunity

Topical therapy can help safely reduce side effect of cancer treatment

Study examines mRNA COVID-19 vaccine’s effectiveness across age and gender

Can control theory explain differences in virulence and transmission of SARS-CoV-2?

COVID-19 donor antibodies show broad cross-reactivity against SARS-CoV-2 variants and related viruses

Peptide nucleocapsid vaccine candidate elicits protective T cell immunity against SARS-CoV-2 in vivo

SARS-CoV-2 recruits heme metabolites in antibody evasion

Why do we lose our sense smell/taste with COVID?

Researchers design "nanotraps" to capture and destroy SARS-CoV-2 viruses

SARS-CoV-2 clade linked to disease severity in the early phase of the pandemic

Some heart medications may facilitate SARS-CoV-2 infection through increasing ACE2 receptor levels

Study identifies mechanism behind SARS-CoV-2 viral protein production

What is the role of nanotechnology in the current COVID-19 outbreak?

Nucleocapsid-based vaccines may prevent SARS-CoV-2 dissemination to distal organs

Researchers develop eleven SARS-CoV-2 RBD nanobodies using computational design

Triple mutation in SARS-CoV-2 seen in second wave of COVID-19 in India

Prolactin hormone acts as a major contributor to breast cancer development, studies find

Nanobodies neutralize SARS-CoV-2 in pre-clinical model

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News